Trial Profile
Pharmacokinetic study of nilotinib to determine metabolite activity in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Sep 2014
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Pharmacokinetics
- Sponsors Novartis Institutes for BioMedical Research; Novartis Pharmaceuticals Corporation
- 11 Sep 2014 New trial record